Edaravone

PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON ITS CLINICAL PROGRAM, SUSPENDING SOME NON-PRIORITY CLINICAL TRIALS TO FOCUS ON TWO CLINICAL PROGRAMS Paris, July 10, 2026, 6pm CET AB Science SA (Euronext - FR0010557264 - AB) today provides an update on its clinical development program and announces the discontinuation of certain non-priority clinical studies in order to focus on two clinical programs, the AB8939 program for acute myeloid leukemia and the masitinib program for amyotrophic lateral sclerosis. Following the company’s press release dated April 16 [1], three clinical studies—which the company currently considers non-priority and for which patient enrollment had been suspended—are being discontinued, namely: Phase 2 study (AB20006) of masitinib in mast cell activation syndrome Phase 3 study (AB15003) of masitinib in mastocytosis Phase 3 study (AB20009) of masitinib in progressive forms of multiple sclerosis The discontinuation of these studies is not related to any safety concerns regarding masitinib. The company intends to complete these clinical studies in accordance with applicable regulations. Stéphane Ledermann, Chairman and CEO of AB Science, stated, “This decision to terminate non-priority studies for which recruitment had been suspended and for which there is no prospect of a rapid resumption reflects compliance with regulatory requirements. It is also consistent with our commitment to allocate all necessary resources to ensure the two priority programs are carried out to the highest standards of quality .” Regarding the AB8939 program for acute myeloid leukemia, the company announced [2] the completion of Phase 1, Step 3, evaluating the combination of AB8939 and venetoclax. The next step is to seek authorization from health authorities—based on a preliminary favorable opinion from the study’s Independent Data Monitoring Committee (IDMC)—to initiate Phase 4 of the study, which will evaluate the triple combination of AB8939, venetoclax, and azacitidine. Regarding the Phase 3 program for masitinib in amyotrophic lateral sclerosis, which was approved in 2025 [3] but has not yet begun, the company will update the protocol and its implementation procedures, and will seek authorization from health authorities to resume this study after submitting a substantial amendment. [1] Press release dated April 16, 2026 [2] Press release dated June 29, 2026 [3] Press release dated July 24, 2025 About AB23005 in ALS The AB23005 study is a prospective, multicenter, randomized, double-blind, placebo-controlled, two-arm study conducted in patients with amyotrophic lateral sclerosis (ALS), designed to confirm the efficacy and safety of masitinib (at a dose of 4.5 mg/kg/day in combination with riluzole) compared to riluzole plus placebo after 48 weeks of treatment. The study will include 408 patients (randomized in a 1:1 ratio) with ALS who are experiencing normal disease progression (i.e., a functional decline of less than 1.1 points per month) and who have not experienced a complete loss of function (i.e., a score of at least 1 on each of the 12 items of the ALSFRS-R scale). U.S. patients receiving edaravone will also be eligible to participate in the study, as the use of this medication constitutes a stratification factor. About AB18001 in AML The AB18001 study, titled “A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of AB8939 Administered Intravenously Daily in Patients with Relapsed/Refractory Acute Myeloid Leukemia , ” is designed in several phases. The first part is a dose-escalation study designed to assess the safety and tolerability of AB8939 and to determine the recommended dose for the Phase 2 expansion study. The objective of the Phase 1 study is to determine the maximum tolerated dose (MTD) for the different treatment regimens with AB8939. Phase 1: Determination of the MTD after 3 consecutive days of treatment with AB8939 alone. Phase 2: Determination of the MTD after 14 consecutive days of treatment with AB8939 alone. Phase 3: Determination of the MTD after 14 consecutive days of treatment with AB8939 in combination with venetoclax. Phase 4: Determination of the maximum tolerated dose (MTD) after 14 consecutive days of treatment with AB8939 in combination with venetoclax and azacitidine. About AB Science Founded in 2001, AB Science is a pharmaceutical company specializing in the research, development, and commercialization of protein kinase inhibitors (PKIs), a class of targeted proteins that play a critical role in cellular signaling. Our programs target only diseases with high unmet medical needs—often fatal conditions with low survival rates, rare diseases, or those resistant to first-line treatment. AB Science has independently developed a portfolio of molecules, and its lead compound, masitinib, has already been approved for veterinary use and is currently undergoing clinical development in humans. The Company is headquartered in Paris and is listed on Euronext Paris (Ticker: AB). For more information about the Company, visit the website: Forward-Looking Statements – AB Science This press release contains forward-looking statements. These statements are not historical facts. They include projections and estimates, as well as the assumptions on which they are based, and statements regarding plans, objectives, intentions, and expectations concerning future financial results, events, operations, services, product development and potential, or future performance. These forward-looking statements can often be identified by the words “expect,” “anticipate,” “believe,” “intend,” “estimate,” or “plan,” as well as by other similar terms. Although AB Science believes that these forward-looking statements are reasonable, investors are cautioned that such statements are subject to numerous risks and uncertainties—which are difficult to predict and generally beyond AB Science’s control—that may cause actual results and events to differ materially from those expressed, implied, or projected in the forward-looking information and statements. These risks and uncertainties include, in particular, uncertainties inherent in the development of the Company’s products—which may not be successful—or in the granting of marketing authorizations by the competent authorities, or, more generally, any factors that may affect the ability to commercialize the products developed by AB Science, as well as those developed or identified in public documents published by AB Science. AB Science makes no commitment to update forward-looking information and statements, subject to applicable regulations, in particular Articles 223-1 et seq. of the AMF’s General Regulations. For further information, please contact: AB Science Financial Communications investors@ab-science.com Attachment Clinical Program Update July 2026 VENG VF

FLORHAM PARK, N.J.--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, PhD; hereinafter, “Shionogi”) today announced its continued partnership with the ALS/MND Natural History Consortium (Consortium) to collect real-world data in amyotrophic lateral sclerosis (ALS). The goal of this collaboration is to deepen scientific knowledge of ALS through access to real-world data, including data of approved therapies for ALS, such as RADICAVA ORS® (edaravone). By collaborating with the Consortium, Shionogi is contributing to a broader understanding of ALS as well as the therapeutic effects of currently approved treatments. “A major scientific challenge in ALS is determining how the disease presents and evolves across diverse patient populations in real-world settings. Access to real-world data is critical to addressing this complexity,” said Gustavo A. Suarez Zambrano, M.D., Vice President, Medical Affairs, Rare Disease, Shionogi Inc. “This partnership will advance our knowledge of ALS and help improve care for people living with the disease, reinforcing Shionogi’s deep commitment to research in the ALS community.” The partnership is built around access to NeuroBANK®, a patient-centered observational platform supported by the Neurological Clinical Research Institute (NCRI) at Massachusetts General Hospital (MGH), which enables the collection of high-quality, standardized clinical data during routine clinical visits with minimal additional burden on people living with ALS. To date, over 4,500 people living with ALS from across 18 multidisciplinary clinics in the U.S., Europe, and Israel have enrolled in the study.1 “ALS remains a devastating disease with profound unmet need, underscoring the urgency to further our understanding of disease progression,” said Alexander Sherman, Director of Center for Innovation and Bioinformatics at NCRI and the Consortium’s Principal Investigator. “By collaborating with Shionogi, we aim to deepen our perspective of ALS in real-world settings to generate insights that can support more informed care for people living with the disease.” About RADICAVA ORS® (edaravone) The U.S. Food and Drug Administration (FDA) approved RADICAVA ORS® (edaravone) on May 12, 2022, for the treatment of amyotrophic lateral sclerosis (ALS). In 2024, the FDA granted RADICAVA ORS Orphan Drug Exclusivity based on its major contribution to patient care by providing an oral suspension route of administration that avoids the burdens of IV administration. RADICAVA ORS is taken daily for 14 consecutive days followed by a 14-day drug-free period for the initial treatment cycle. For subsequent treatment cycles, RADICAVA ORS is taken for 10 days within a 14-day period followed by a 14-day drug-free period. Each 105 mg (5mL) dose of RADICAVA ORS should be taken in the morning after overnight fasting. Patients should not eat or drink (except water) within one hour after taking RADICAVA ORS.2 Edaravone was discovered and developed for ALS by Tanabe Pharma Corporation and commercialized in the U.S. by Tanabe Pharma America, Inc. The Tanabe Pharma group companies began researching ALS in 2001 through an iterative clinical platform over a 13-year period. In 2015, edaravone was approved as RADICUT® for the treatment of ALS in Japan and South Korea. Marketing authorizations were subsequently granted in Canada (October 2018), Switzerland (January 2019), Indonesia (July 2020), Thailand (April 2021), Malaysia (December 2021), Australia (February 2023) and Brazil (February 2024). Marketing authorization for RADICAVA® Oral Suspension was granted in Canada (November 2022) and Switzerland (May 2023), and RADICUT® Oral Suspension 2.1% was granted regulatory approval in Japan in December 2022. To date, in the U.S., RADICAVA ORS, along with the previously available IV RADICAVA® (edaravone), have been used to treat over 22,800 people with ALS, with over 3.0-million days of therapy, and have been prescribed by over 2,850 HCPs.3 Following the completion of Shionogi’s acquisition of the global RADICAVA business, Shionogi now holds global rights to RADICAVA ORS and RADICAVA IV. INDICATION RADICAVA ORS® (edaravone) is indicated for the treatment of amyotrophic lateral sclerosis (ALS). IMPORTANT SAFETY INFORMATION Hypersensitivity Reactions RADICAVA ORS® (edaravone) is contraindicated in patients with a history of hypersensitivity to edaravone or any of the inactive ingredients of this product. Hypersensitivity reactions (redness, wheals, and erythema multiforme) and cases of anaphylaxis (urticaria, decreased blood pressure, and dyspnea) have occurred. Patients should be monitored carefully for hypersensitivity reactions. If hypersensitivity reactions occur, discontinue RADICAVA ORS, treat per standard of care, and monitor until the condition resolves. Sulfite Allergic Reactions RADICAVA ORS contain sodium bisulfite, a sulfite that may cause allergic-type reactions, including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown but occurs more frequently in asthmatic people. Adverse Reactions The most common adverse reactions (≥10%) reported in RADICAVA® (edaravone)-treated patients and at least 2% more frequently than placebo were contusion (15% vs 9%), gait disturbance (13% vs 9%), and headache (10% vs 6%), respectively. In an open label study, fatigue was also observed in 7.6% of patients receiving RADICAVA ORS. Pregnancy Based on animal data, RADICAVA ORS may cause fetal harm. To report suspected adverse reactions or product complaints, contact Shionogi Inc., at 1-888-292-0058. You may also report suspected adverse reactions to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Please see the full Prescribing Information, also available at http://www.RADICAVAORS.com About ALS ALS (Amyotrophic Lateral Sclerosis) is a progressive neurodegenerative disease characterized by the selective degeneration and loss of motor neurons, leading to muscle weakness and respiratory impairment. After onset, muscle atrophy gradually progresses, and ultimately respiratory muscle paralysis severely impacts life expectancy. Globally, the annual incidence is estimated at approximately 1–2 cases per 100,000 population, making it a rare disease for which no fundamental cure currently exists.4 Multiple factors, including oxidative stress and glutamate-induced excitotoxicity, are involved in its pathophysiology, and treatment options to slow disease progression remain extremely limited. For this reason, ALS is recognized as a disease with a high level of unmet medical need, and the development and delivery of innovative therapies are strongly required. About the ALS/MND Natural History Consortium The ALS/MND Natural History Consortium, comprising academic medical centers across the U.S., Europe, and Israel, is driving efforts to transform our understanding of ALS and related motor neuron diseases. Through its network of multidisciplinary clinics, the Consortium captures rich, longitudinal, real-world data from people living with ALS. By sharing these insights with researchers worldwide, it is accelerating discovery, informing smarter clinical trial design, and advancing better treatment and care for those living with the disease. About Shionogi in Rare Disease Shionogi is committed to the research and development of innovative medicines that address unmet medical needs for people worldwide. Rare diseases often have limited treatment options and affect the lives of individuals and families around the world. In the U.S., Shionogi is advancing a rare disease franchise that includes an approved therapy for amyotrophic lateral sclerosis (ALS) as well as clinical programs in Fragile X syndrome, Jordan’s Syndrome and Pompe disease. For more information, view our pipeline here: https://www.shionogi.com/us/en/innovation/pipeline.html. About Shionogi & Co., Ltd. Shionogi & Co., Ltd. is a 148-year-old global, research-driven pharmaceutical company headquartered in Osaka, Japan, that is dedicated to bringing benefits to patients based on its corporate philosophy of “supplying the best possible medicine to protect the health and wellbeing of the patients we serve.” The company currently markets products in several therapeutic areas including anti-infectives, pain, CNS disorders and cardiovascular diseases. Shionogi’s research and development currently targets two therapeutic areas: infectious diseases and diseases with unmet medical needs in pain/CNS, including Alzheimer’s disease, oncology, rare diseases, and sleep apnea. For more information on Shionogi & Co., Ltd., please visit https://www.shionogi.com/global/en. Forward-Looking Statements This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, lack of availability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise. References The Center for Innovation & Bioinformatics. ALS/MND Natural History Consortium. (2023). 22 May 2026. Available at: https://www.data4cures.org/natural-history-consortium . RADICAVA and RADICAVA ORS Prescribing Information. Florham Park, NJ: Shionogi Inc.; 2026. Data on file. Shionogi Inc. Xu, et al. Global variation in prevalence and incidence of amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol. 2020 Apr;267(4):944-953. DOI: 10.1007/s00415-019-09652-y